Eva Marchese shares her thoughts on the challenges in IO therapies with In Vivo. As more and more immuno-oncology products reach the market, the sustainability challenge persists: biopharmaceutical companies are seeking fair reimbursement deals that recognize their innovations, and struggling health care systems worldwide are pushing the burden of proof back onto the shoulders of drug developers.
Access the full article below.
Curative cell and gene therapies and healthcare system disruption
Potentially curative cell and gene therapies represent a key shift in patient care and will have considerable impact across the patient journey, affecting the...